INVO Fertility Inc IVF Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$2.14 up $0.11, 5.42% at close Nov 6
Last close · Previous close $2.03
- Market cap
- At the Nov 6 close
- P/E ratio
- On last 12 months’ EPS
- Diluted EPS
- Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$2.14down $1.04, 32.71%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$2.03Nov 5
- Volume37.02KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume34.93KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $1.59 to $98.00; now $2.14
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
IVF trailed the S&P 500 in all 7 periods.
| Period | IVF and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | IVF: down 32.7% S&P 500: down 5.6% | IVF trailed the S&P 500 by 27.1 percentage points Trailed |
| 3M | IVF: down 48.6% S&P 500: down 4.1% | IVF trailed the S&P 500 by 44.5 percentage points Trailed |
| YTD | IVF: down 85.8% S&P 500: up 8.7% | IVF trailed the S&P 500 by 94.5 percentage points Trailed |
| 1Y | IVF: down 97.3% S&P 500: up 10.9% | IVF trailed the S&P 500 by 108.2 percentage points Trailed |
| Long term | ||
| 3Y | IVF: down 100.0% S&P 500: up 75.0% −93.2% vs +20.5% a year | IVF trailed the S&P 500 by 175.0 percentage points Trailed |
| 5Y | IVF: down 100.0% S&P 500: up 67.8% −91.1% vs +10.9% a year | IVF trailed the S&P 500 by 167.8 percentage points Trailed |
| 10Y | IVF: down 100.0% S&P 500: up 313.1% −73.4% vs +15.2% a year | IVF trailed the S&P 500 by 413.1 percentage points Trailed |
$10,000 invested in IVF 10 years ago (Nov 4, 2016) would be worth about $0 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
IVF trailed the S&P 500 in all 7 periods.
| Period | IVF and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | IVF: down 32.7% S&P 500: down 5.6% | IVF trailed the S&P 500 by 27.1 percentage points Trailed |
| 3M | IVF: down 48.6% S&P 500: down 4.3% | IVF trailed the S&P 500 by 44.3 percentage points Trailed |
| YTD | IVF: down 85.8% S&P 500: up 7.8% | IVF trailed the S&P 500 by 93.6 percentage points Trailed |
| 1Y | IVF: down 97.3% S&P 500: up 9.7% | IVF trailed the S&P 500 by 107.0 percentage points Trailed |
| Long term | ||
| 3Y | IVF: down 100.0% S&P 500: up 68.8% −93.2% vs +19.1% a year | IVF trailed the S&P 500 by 168.8 percentage points Trailed |
| 5Y | IVF: down 100.0% S&P 500: up 56.9% −91.1% vs +9.4% a year | IVF trailed the S&P 500 by 156.9 percentage points Trailed |
| 10Y | IVF: down 100.0% S&P 500: up 252.6% −73.4% vs +13.4% a year | IVF trailed the S&P 500 by 352.6 percentage points Trailed |
$10,000 invested in IVF 10 years ago (Nov 4, 2016) would be worth about $0 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$4,726,153.85
Closing high on . Now 100.0% below that record.
Split-adjusted daily closes since May 21, 2012.
Stock splits
8
Latest: 1-for-4 on . Share counts adjust after each split.
All 8 splits
- 1-for-4
- 1-for-5
- 1-for-8
- 1-for-3
- 1-for-12
- 1-for-20
- 5-for-8
- 1-for-20
Valuation
Financials
About INVO Fertility Inc
NAYA Biosciences is a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health. Our proven hub & spoke model harnesses the shared resources of a parent company and agility of lean strategic franchises, enabling efficient acquisition, development, and partnering of assets and allowing for optimized return on investment by combining scalable, profitable commercial revenues with the upside of innovative clinical-stage therapeutics. NAYA’s expanding portfolio of assets currently includes NY-303, a GPC3 x NKp46 bifunctional antibody for the treatment of hepatocellular carcinoma (HCC) with a unique mode of action targeting non-responders to the current immunotherapy standard of care (approximately 70% of the current treatable market) cleared to enroll patients in a Phase 1/2a monotherapy trial in 2025, NY-338, a CD38 x NKp46 bifunctional antibody for the treatment of multiple myeloma and autoimmune diseases with a differentiated safety and efficacy profile, NY-500, a PD-1 x VEGF bifunctional antibody for the treatment of HCC and other solid tumors, and NY-600 a PSMA x NKp46 bifunctional antibody for the treatment of metastatic Castration Resistant Prostate Cancer (mCRPC).
- Sector
- Industry
- Headquarters
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
IVF news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
IVF stock FAQ
What is IVF stock’s price today?
INVO Fertility (IVF) traded at $2.14 at the close on , up $0.11 (5.42%) from the previous close of $2.03. Over the past 52 weeks it has traded between $1.59 and $98.00.
If you invested $1,000 in IVF 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in IVF on would be worth about $0 at the close on , a total return of −100.0%. The same $1,000 would be worth $0 if invested five years ago and $27 if invested one year ago. Past performance doesn’t predict future returns.
Does IVF pay a dividend?
INVO Fertility hasn’t paid a dividend in the last twelve months.
What is IVF’s 52-week high and low?
Over the past 52 weeks IVF has traded as low as $1.59 and as high as $98.00. At $2.14 at the close on , it is 97.8% below that high and 34.6% above the low.
What is IVF’s all-time high?
IVF’s highest closing price was $4,726,153.85 on , adjusted for stock splits. At $2.14 at the close on , it is 100.0% below that record.
Has IVF stock ever split?
Yes, eight times: 1-for-20 on ; 5-for-8 on ; 1-for-20 on ; 1-for-12 on ; 1-for-3 on ; 1-for-8 on ; 1-for-5 on ; 1-for-4 on .
How has IVF stock performed?
Including dividends and measured to the close on , IVF has returned −85.8% so far this year and −97.3% over the past year, and −100.0% over five years (−91.1% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What exchange does IVF trade on?
INVO Fertility trades on the Nasdaq under the ticker symbol IVF. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.